Thomas M. Farley

781 total citations
42 papers, 406 citations indexed

About

Thomas M. Farley is a scholar working on Molecular Biology, Organic Chemistry and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Thomas M. Farley has authored 42 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 6 papers in Organic Chemistry and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Thomas M. Farley's work include Coenzyme Q10 studies and effects (10 papers), Physiological and biochemical adaptations (5 papers) and Pharmaceutical Practices and Patient Outcomes (4 papers). Thomas M. Farley is often cited by papers focused on Coenzyme Q10 studies and effects (10 papers), Physiological and biochemical adaptations (5 papers) and Pharmaceutical Practices and Patient Outcomes (4 papers). Thomas M. Farley collaborates with scholars based in United States. Thomas M. Farley's co-authors include Karl Folkers, Barry L. Carter, Jean Scholler, Karen B. Farris, Clair B. Stalnaker, F. M. Strong, Joseph E. Sniezek, Joakim Nilsson, James C. Wohlleb and Jon Y. Takemoto and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Thomas M. Farley

38 papers receiving 364 citations

Peers

Thomas M. Farley

PFM

PHEOH

Z. Verjee Canada

Robert C. Wood United States

M Welsch France

So Jung Park South Korea

Christine Murphy United States

María José Muñoz Spain

S. Roy France

Curtis Harper United States

Miguel Martı́-Cabrera Spain

Donald S. McLaren Lebanon

Z. Verjee Canada

Thomas M. Farley

106 ×0.7

29 ×0.4

6 ×0.1

PFM

12 ×0.3

49 ×1.2

PHEOH

Citations per year, relative to Thomas M. Farley Thomas M. Farley (= 1×) peers Z. Verjee

Countries citing papers authored by Thomas M. Farley

Since Specialization

Citations

This map shows the geographic impact of Thomas M. Farley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Farley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Farley more than expected).

Fields of papers citing papers by Thomas M. Farley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. Farley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Farley. The network helps show where Thomas M. Farley may publish in the future.

Co-authorship network of co-authors of Thomas M. Farley

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. Farley. A scholar is included among the top collaborators of Thomas M. Farley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. Farley. Thomas M. Farley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Farley, Thomas M., et al.. (2024). Successful oral phytonadione (vitamin K) challenge following an infusion-related reaction to intravenous phytonadione. BMJ Case Reports. 17(11). e261987–e261987.

Farley, Thomas M.. (2023). Hypertensive Emergency: Parenteral Antihypertensives and Population Data. Current Hypertension Reports. 25(12). 423–428. 1 indexed citations

Williams, Amber L., et al.. (2020). Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection. BMJ Case Reports. 13(10). e239210–e239210. 8 indexed citations

Farley, Thomas M.. (2019). 546: ENOXAPARIN-RELATED FATAL SPONTANEOUS RETROPERITONEAL HEMORRHAGE. Critical Care Medicine. 48(1). 254–254.

Farley, Thomas M., et al.. (2017). Comparison of the Safety and Effectiveness of Apixaban versus Warfarin in Patients with Severe Renal Impairment: An Alternative Viewpoint. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 37(10). e107–e108. 1 indexed citations

Farley, Thomas M., et al.. (2017). False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use. BMJ Case Reports. 2017. bcr–2017. 2 indexed citations

Farley, Thomas M., et al.. (2016). Reversal of anticoagulation with four-factor prothrombin complex concentrate without concurrent vitamin K (phytonadione) for urgent surgery in a patient at moderate-to-high risk for thromboembolism. BMJ Case Reports. 2016. bcr2016217092–bcr2016217092. 2 indexed citations

Farley, Thomas M., et al.. (2015). Physician-Pharmacist collaboration in a pay for performance healthcare environment. Bratislavské lekárske listy/Bratislava medical journal. 116(9). 517–519. 2 indexed citations

Farley, Thomas M., et al.. (2014). Effect of clinical pharmacist intervention on medication discrepancies following hospital discharge. International Journal of Clinical Pharmacy. 36(2). 430–437. 53 indexed citations

10.

Peter, Wendy L. St., Thomas M. Farley, & Barry L. Carter. (2011). Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients. Current Opinion in Nephrology & Hypertension. 20(5). 498–503. 10 indexed citations

11.

Farley, Thomas M., et al.. (2009). In the Pipeline: New Oral Anticoagulants for the Prevention of Venous Thromboembolism. Orthopedics. 32(1). 35–39. 1 indexed citations

12.

Farley, Thomas M., et al.. (1994). Secondary disabilities in Arkansas with spina bifida.. PubMed. 4 Suppl 1. 39–40. 7 indexed citations

13.

Farley, Thomas M., et al.. (1993). Traumatic spinal cord injury in Arkansas, 1980 to 1989. Archives of Physical Medicine and Rehabilitation. 74(10). 1035–1040. 49 indexed citations

14.

Stalnaker, Clair B., et al.. (1979). Comparative physical and physiological performance of rainbow trout, Salmo gairdneri, of distinct lactate dehydrogenase B2 phenotypes. Comparative Biochemistry and Physiology Part A Physiology. 63(2). 229–235. 20 indexed citations

15.

Scholler, Jean, Thomas M. Farley, & Karl Folkers. (1968). Response of mice with genetic dystrophy to therapy with coenzyme Q.. PubMed. 38(3). 369–75. 3 indexed citations

16.

Farley, Thomas M., G. Doyle Daves, & Karl Folkers. (1968). Mass spectrometry of ubiquinones. Thermal loss of a methoxyl group. The Journal of Organic Chemistry. 33(2). 905–907. 2 indexed citations

17.

Nilsson, Joakim, Thomas M. Farley, Jean Scholler, & Karl Folkers. (1968). Biosynthesis and levels of coenzyme Q in genetically dystrophic mice. Archives of Biochemistry and Biophysics. 123(2). 422–426. 9 indexed citations

18.

Farley, Thomas M., Jean Scholler, Jack L. Smith, Karl Folkers, & Coy D. Fitch. (1967). Hematopoietic activity of hexahydrocoenzyme Q4 in the monkey. Archives of Biochemistry and Biophysics. 121(3). 625–632. 11 indexed citations

19.

Farley, Thomas M., Jean Scholler, & Karl Folkers. (1966). Response of genetically dystrophic mice to therapy with hexahydrocoenzyme Q4. Biochemical and Biophysical Research Communications. 24(3). 299–303. 21 indexed citations

20.

Farley, Thomas M., et al.. (1965). The Chemistry of Antimycin A. XII. Dissociation Constants and Iron(III) Chelates of Antimycin A₃ and Some Analogs¹. Journal of the American Chemical Society. 87(15). 3501–3504. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact